6 Related NICE guidance
Details are correct at the time of publication. Further information is available on the NICE website.
Published
-
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 254 (2012).
-
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 127 (2007).
-
Management of multiple sclerosis in primary and secondary care. NICE clinical guideline 8 (2003).
-
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE technology appraisal guidance 32 (2002).
Under development
NICE is developing the following guidance (details available from www.nice.org.uk):
-
Dimethyl fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal. Publication expected January 2014.
-
Alemtuzumab for treating relapsing–remitting multiple sclerosis. NICE technology appraisal. Publication expected April 2014.
-
Laquinimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal. Publication expected February 2014.